IAPP and myeloid sarcoma: At present, NEP appears an interesting target in MS since data coming from experimental studies support a role in ameliorating EAE severity through catabolism of several vasoactive peptides, including those of the amylin family and endogenous opioids such as met-enkephalin [260].